| Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers S Havervall, A Rosell, M Phillipson, SM Mangsbo, P Nilsson, S Hober, ... Jama 325 (19), 2015-2016, 2021 | 410 | 2021 |
| SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden AS Rudberg, S Havervall, A Månberg, A Jernbom Falk, K Aguilera, H Ng, ... Nature communications 11 (1), 5064, 2020 | 322 | 2020 |
| Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality—brief report A Rosell, S Havervall, F von Meijenfeldt, Y Hisada, K Aguilera, SP Grover, ... Arteriosclerosis, Thrombosis, and Vascular Biology 41 (2), 878-882, 2021 | 185 | 2021 |
| Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19 H Ng, S Havervall, A Rosell, K Aguilera, K Parv, FA von Meijenfeldt, ... Arteriosclerosis, thrombosis, and vascular biology 41 (2), 988-994, 2021 | 174 | 2021 |
| Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection S Havervall, U Marking, J Svensson, N Greilert-Norin, P Bacchus, ... New England Journal of Medicine 387 (14), 1333-1336, 2022 | 133 | 2022 |
| Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge FA von Meijenfeldt, S Havervall, J Adelmeijer, A Lundström, ... Blood advances 5 (3), 756-759, 2021 | 106 | 2021 |
| Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality FA von Meijenfeldt, S Havervall, J Adelmeijer, A Lundström, AS Rudberg, ... Research and practice in thrombosis and haemostasis 5 (1), 132-141, 2021 | 82 | 2021 |
| Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19 S Havervall, H Ng, A Jernbom Falk, N Greilert‐Norin, A Månberg, ... Journal of internal medicine 291 (1), 72-80, 2022 | 59 | 2022 |
| Soluble angiotensin‐converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers A Lundström, L Ziegler, S Havervall, AS Rudberg, F Von Meijenfeldt, ... Journal of Medical Virology 93 (10), 5908-5916, 2021 | 59 | 2021 |
| Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 S Havervall, U Marking, N Greilert-Norin, H Ng, M Gordon, ... EBioMedicine 70, 2021 | 46 | 2021 |
| SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection S Havervall, A Jernbom Falk, J Klingström, H Ng, N Greilert-Norin, ... PloS One 17 (1), e0262169, 2022 | 42 | 2022 |
| 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection U Marking, O Bladh, S Havervall, J Svensson, N Greilert-Norin, K Aguilera, ... The Lancet Infectious Diseases 23 (2), 150-152, 2023 | 34 | 2023 |
| Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants V Monteil, B Eaton, E Postnikova, M Murphy, B Braunsfeld, I Crozier, ... EMBO Molecular Medicine 14 (8), e15230, 2022 | 34 | 2022 |
| Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection K Blom, U Marking, S Havervall, NG Norin, M Gordon, M García, ... The Lancet Infectious Diseases 22 (7), 943-945, 2022 | 34 | 2022 |
| Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2 N Roxhed, A Bendes, M Dale, C Mattsson, L Hanke, T Dodig-Crnković, ... Nature Communications 12 (1), 3695, 2021 | 31 | 2021 |
| Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma R Zenlander, S Havervall, M Magnusson, J Engstrand, A Ågren, C Thålin, ... Scientific Reports 11 (1), 18025, 2021 | 30 | 2021 |
| Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay S Hober, C Hellström, J Olofsson, E Andersson, S Bergström, ... Clinical & Translational Immunology 10 (7), e1312, 2021 | 29 | 2021 |
| Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time S Havervall, U Marking, N Greilert‐Norin, M Gordon, H Ng, W Christ, ... Clinical & Translational Immunology 11 (4), e1388, 2022 | 25 | 2022 |
| High prevalence of olfactory disorders 18 months after contracting COVID-19 A Tognetti, E Thunell, MJ Olsson, N Greilert, S Havervall, C Thålin, ... Otolaryngology 10 (2022.01), 20.22269490, 2022 | 17* | 2022 |
| COVID-19 is associated with an acquired factor XIII deficiency FA von Meijenfeldt, S Havervall, J Adelmeijer, A Lundström, ... Thrombosis and Haemostasis 121 (12), 1668-1669, 2021 | 15 | 2021 |
